According to new survey, global Familial Amyloid Polyneuropathy Therapeutic market is projected to reach US$ 2067.8 million in 2029, increasing from US$ 1387 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029.

Familial Amyloid Polyneuropathy Therapeutic Market

Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).

The global familial amyloid polyneuropathy (FAP) therapeutic market refers to the market for treatments and therapies aimed at managing and treating familial amyloid polyneuropathy, also known as transthyretin amyloidosis (ATTR). FAP is a rare, progressive, and potentially fatal genetic disorder that affects the peripheral nerves and can lead to various symptoms and complications.

Here are some key points related to the global FAP therapeutic market:

Market Overview: The market for FAP therapeutics includes pharmaceutical drugs, gene therapies, and other treatment options aimed at managing the symptoms and halting the progression of the disease.

Disease-Modifying Therapies: The development of disease-modifying therapies targeting the underlying cause of FAP is a significant focus in this market. These therapies aim to reduce the buildup of abnormal amyloid proteins in the peripheral nerves, which is a hallmark of FAP.

TTR Stabilizers: TTR (transthyretin) stabilizers are pharmacological agents that aim to stabilize the mutated TTR protein and prevent its misfolding and aggregation. Several TTR stabilizers have been approved or are under investigation for their efficacy in treating FAP.

RNA Interference (RNAi) Therapies: RNAi therapies, such as patisiran and inotersen, work by reducing the production of the TTR protein by interfering with the mRNA responsible for its synthesis. These therapies have shown promise in clinical trials and have been approved for the treatment of FAP in some regions.

Liver Transplantation: In some cases, liver transplantation may be considered as a treatment option for FAP. As the liver produces most of the circulating TTR, replacing the diseased liver with a healthy one can halt the production of mutant TTR and slow down the progression of the disease.

Geographic Considerations: The global FAP therapeutic market is influenced by factors such as regional prevalence, healthcare infrastructure, regulatory environments, and reimbursement policies across different countries and regions.

Ongoing Research and Development: The FAP therapeutic market is dynamic, with ongoing research and development efforts focusing on novel therapies and treatment modalities. This includes gene therapies, small molecule inhibitors, and other approaches aimed at providing effective and targeted treatments for FAP.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Familial Amyloid Polyneuropathy Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Familial Amyloid Polyneuropathy Therapeutic Market Report

Report Metric	Details
Report Name	Familial Amyloid Polyneuropathy Therapeutic Market
Accounted market size in 2022	US$ 1387 million
Forecasted market size in 2029	US$ 2067.8 million
CAGR	5.9%
Base Year	2022
Forecasted years	2023 - 2029
Segment by Type	Inotersen Tafamidis Patisiran Others
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences, Arcturus Therapeutics Inc, Prothena Corporation, Eidos Therapeutics, FoldRx Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline (GSK), Greenovation Biotech GmbH
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

FAQ for this report

How fast is Familial Amyloid Polyneuropathy Therapeutic Market growing?

Ans: The Familial Amyloid Polyneuropathy Therapeutic Market witnessing a CAGR of 5.9% during the forecast period 2023-2029.

What is the Familial Amyloid Polyneuropathy Therapeutic Market size in 2029?

Ans: The Familial Amyloid Polyneuropathy Therapeutic Market size in 2029 will be US$ 2067.8 million.

Who are the main players in the Familial Amyloid Polyneuropathy Therapeutic Market report?

Ans: The main players in the Familial Amyloid Polyneuropathy Therapeutic Market are Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences, Arcturus Therapeutics Inc, Prothena Corporation, Eidos Therapeutics, FoldRx Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline (GSK), Greenovation Biotech GmbH

What are the Application segmentation covered in the Familial Amyloid Polyneuropathy Therapeutic Market report?

Ans: The Applications covered in the Familial Amyloid Polyneuropathy Therapeutic Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others

What are the Type segmentation covered in the Familial Amyloid Polyneuropathy Therapeutic Market report?

Ans: The Types covered in the Familial Amyloid Polyneuropathy Therapeutic Market report are Inotersen, Tafamidis, Patisiran, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Inotersen

1.2.3 Tafamidis

1.2.4 Patisiran

1.2.5 Others

1.3 Market by Application

1.3.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Perspective (2018-2029)

2.2 Familial Amyloid Polyneuropathy Therapeutic Growth Trends by Region

2.2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Region (2018-2023)

2.2.3 Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Region (2024-2029)

2.3 Familial Amyloid Polyneuropathy Therapeutic Market Dynamics

2.3.1 Familial Amyloid Polyneuropathy Therapeutic Industry Trends

2.3.2 Familial Amyloid Polyneuropathy Therapeutic Market Drivers

2.3.3 Familial Amyloid Polyneuropathy Therapeutic Market Challenges

2.3.4 Familial Amyloid Polyneuropathy Therapeutic Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Revenue

3.1.1 Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Revenue (2018-2023)

3.1.2 Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Players (2018-2023)

3.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Familial Amyloid Polyneuropathy Therapeutic Revenue

3.4 Global Familial Amyloid Polyneuropathy Therapeutic Market Concentration Ratio

3.4.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Familial Amyloid Polyneuropathy Therapeutic Revenue in 2022

3.5 Familial Amyloid Polyneuropathy Therapeutic Key Players Head office and Area Served

3.6 Key Players Familial Amyloid Polyneuropathy Therapeutic Product Solution and Service

3.7 Date of Enter into Familial Amyloid Polyneuropathy Therapeutic Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Familial Amyloid Polyneuropathy Therapeutic Breakdown Data by Type

4.1 Global Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Type (2018-2023)

4.2 Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Type (2024-2029)

5 Familial Amyloid Polyneuropathy Therapeutic Breakdown Data by Application

5.1 Global Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Application (2018-2023)

5.2 Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Application (2024-2029)

6 North America

6.1 North America Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)

6.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2023)

6.4 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)

7.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2023)

7.4 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)

8.2 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2018-2023)

8.4 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)

9.2 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2023)

9.4 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)

10.2 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2023)

10.4 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer Inc.

11.1.1 Pfizer Inc. Company Detail

11.1.2 Pfizer Inc. Business Overview

11.1.3 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction

11.1.4 Pfizer Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.1.5 Pfizer Inc. Recent Development

11.2 Alnylam Pharmaceuticals Inc.

11.2.1 Alnylam Pharmaceuticals Inc. Company Detail

11.2.2 Alnylam Pharmaceuticals Inc. Business Overview

11.2.3 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction

11.2.4 Alnylam Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.2.5 Alnylam Pharmaceuticals Inc. Recent Development

11.3 Ionis Pharmaceuticals Inc.

11.3.1 Ionis Pharmaceuticals Inc. Company Detail

11.3.2 Ionis Pharmaceuticals Inc. Business Overview

11.3.3 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction

11.3.4 Ionis Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.3.5 Ionis Pharmaceuticals Inc. Recent Development

11.4 Corino Therapeutics Inc.

11.4.1 Corino Therapeutics Inc. Company Detail

11.4.2 Corino Therapeutics Inc. Business Overview

11.4.3 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction

11.4.4 Corino Therapeutics Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.4.5 Corino Therapeutics Inc. Recent Development

11.5 Proclara Biosciences

11.5.1 Proclara Biosciences Company Detail

11.5.2 Proclara Biosciences Business Overview

11.5.3 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Introduction

11.5.4 Proclara Biosciences Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.5.5 Proclara Biosciences Recent Development

11.6 Arcturus Therapeutics Inc

11.6.1 Arcturus Therapeutics Inc Company Detail

11.6.2 Arcturus Therapeutics Inc Business Overview

11.6.3 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Introduction

11.6.4 Arcturus Therapeutics Inc Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.6.5 Arcturus Therapeutics Inc Recent Development

11.7 Prothena Corporation

11.7.1 Prothena Corporation Company Detail

11.7.2 Prothena Corporation Business Overview

11.7.3 Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Introduction

11.7.4 Prothena Corporation Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.7.5 Prothena Corporation Recent Development

11.8 Eidos Therapeutics

11.8.1 Eidos Therapeutics Company Detail

11.8.2 Eidos Therapeutics Business Overview

11.8.3 Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Introduction

11.8.4 Eidos Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.8.5 Eidos Therapeutics Recent Development

11.9 FoldRx Pharmaceuticals

11.9.1 FoldRx Pharmaceuticals Company Detail

11.9.2 FoldRx Pharmaceuticals Business Overview

11.9.3 FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Introduction

11.9.4 FoldRx Pharmaceuticals Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.9.5 FoldRx Pharmaceuticals Recent Development

11.10 Akcea Therapeutics

11.10.1 Akcea Therapeutics Company Detail

11.10.2 Akcea Therapeutics Business Overview

11.10.3 Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Introduction

11.10.4 Akcea Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.10.5 Akcea Therapeutics Recent Development

11.11 GlaxoSmithKline (GSK)

11.11.1 GlaxoSmithKline (GSK) Company Detail

11.11.2 GlaxoSmithKline (GSK) Business Overview

11.11.3 GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Introduction

11.11.4 GlaxoSmithKline (GSK) Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.11.5 GlaxoSmithKline (GSK) Recent Development

11.12 Greenovation Biotech GmbH

11.12.1 Greenovation Biotech GmbH Company Detail

11.12.2 Greenovation Biotech GmbH Business Overview

11.12.3 Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Introduction

11.12.4 Greenovation Biotech GmbH Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

11.12.5 Greenovation Biotech GmbH Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Pfizer Inc

Alnylam Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Corino Therapeutics, Inc

Proclara Biosciences

Arcturus Therapeutics Inc

Eidos Therapeutics

Akcea Therapeutics

GlaxoSmithKline(GSK )

greenovation Biotech GmbH

Prothena Corporation

FoldRx Pharmaceuticals

List of Tables

Table 1. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Inotersen

Table 3. Key Players of Tafamidis

Table 4. Key Players of Patisiran

Table 5. Key Players of Others

Table 6. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

Table 7. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

Table 8. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2018-2023) & (US$ Million)

Table 9. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2018-2023)

Table 10. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Region (2024-2029) & (US$ Million)

Table 11. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2024-2029)

Table 12. Familial Amyloid Polyneuropathy Therapeutic Market Trends

Table 13. Familial Amyloid Polyneuropathy Therapeutic Market Drivers

Table 14. Familial Amyloid Polyneuropathy Therapeutic Market Challenges

Table 15. Familial Amyloid Polyneuropathy Therapeutic Market Restraints

Table 16. Global Familial Amyloid Polyneuropathy Therapeutic Revenue by Players (2018-2023) & (US$ Million)

Table 17. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Players (2018-2023)

Table 18. Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy Therapeutic as of 2022)

Table 19. Ranking of Global Top Familial Amyloid Polyneuropathy Therapeutic Companies by Revenue (US$ Million) in 2022

Table 20. Global 5 Largest Players Market Share by Familial Amyloid Polyneuropathy Therapeutic Revenue (CR5 and HHI) & (2018-2023)

Table 21. Key Players Headquarters and Area Served

Table 22. Key Players Familial Amyloid Polyneuropathy Therapeutic Product Solution and Service

Table 23. Date of Enter into Familial Amyloid Polyneuropathy Therapeutic Market

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2023) & (US$ Million)

Table 26. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Type (2018-2023)

Table 27. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Type (2024-2029) & (US$ Million)

Table 28. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Type (2024-2029)

Table 29. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2023) & (US$ Million)

Table 30. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Application (2018-2023)

Table 31. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Application (2024-2029) & (US$ Million)

Table 32. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Application (2024-2029)

Table 33. North America Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

Table 34. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2023) & (US$ Million)

Table 35. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029) & (US$ Million)

Table 36. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

Table 37. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2023) & (US$ Million)

Table 38. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029) & (US$ Million)

Table 39. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

Table 40. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2018-2023) & (US$ Million)

Table 41. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2024-2029) & (US$ Million)

Table 42. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

Table 43. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2023) & (US$ Million)

Table 44. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029) & (US$ Million)

Table 45. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

Table 46. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2023) & (US$ Million)

Table 47. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029) & (US$ Million)

Table 48. Pfizer Inc. Company Detail

Table 49. Pfizer Inc. Business Overview

Table 50. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product

Table 51. Pfizer Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 52. Pfizer Inc. Recent Development

Table 53. Alnylam Pharmaceuticals Inc. Company Detail

Table 54. Alnylam Pharmaceuticals Inc. Business Overview

Table 55. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product

Table 56. Alnylam Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 57. Alnylam Pharmaceuticals Inc. Recent Development

Table 58. Ionis Pharmaceuticals Inc. Company Detail

Table 59. Ionis Pharmaceuticals Inc. Business Overview

Table 60. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product

Table 61. Ionis Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 62. Ionis Pharmaceuticals Inc. Recent Development

Table 63. Corino Therapeutics Inc. Company Detail

Table 64. Corino Therapeutics Inc. Business Overview

Table 65. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product

Table 66. Corino Therapeutics Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 67. Corino Therapeutics Inc. Recent Development

Table 68. Proclara Biosciences Company Detail

Table 69. Proclara Biosciences Business Overview

Table 70. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product

Table 71. Proclara Biosciences Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 72. Proclara Biosciences Recent Development

Table 73. Arcturus Therapeutics Inc Company Detail

Table 74. Arcturus Therapeutics Inc Business Overview

Table 75. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product

Table 76. Arcturus Therapeutics Inc Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 77. Arcturus Therapeutics Inc Recent Development

Table 78. Prothena Corporation Company Detail

Table 79. Prothena Corporation Business Overview

Table 80. Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Product

Table 81. Prothena Corporation Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 82. Prothena Corporation Recent Development

Table 83. Eidos Therapeutics Company Detail

Table 84. Eidos Therapeutics Business Overview

Table 85. Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product

Table 86. Eidos Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 87. Eidos Therapeutics Recent Development

Table 88. FoldRx Pharmaceuticals Company Detail

Table 89. FoldRx Pharmaceuticals Business Overview

Table 90. FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Product

Table 91. FoldRx Pharmaceuticals Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 92. FoldRx Pharmaceuticals Recent Development

Table 93. Akcea Therapeutics Company Detail

Table 94. Akcea Therapeutics Business Overview

Table 95. Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product

Table 96. Akcea Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 97. Akcea Therapeutics Recent Development

Table 98. GlaxoSmithKline (GSK) Company Detail

Table 99. GlaxoSmithKline (GSK) Business Overview

Table 100. GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Product

Table 101. GlaxoSmithKline (GSK) Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 102. GlaxoSmithKline (GSK) Recent Development

Table 103. Greenovation Biotech GmbH Company Detail

Table 104. Greenovation Biotech GmbH Business Overview

Table 105. Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Product

Table 106. Greenovation Biotech GmbH Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023) & (US$ Million)

Table 107. Greenovation Biotech GmbH Recent Development

Table 108. Research Programs/Design for This Report

Table 109. Key Data Information from Secondary Sources

Table 110. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Comparison by Type (2023-2029) & (US$ Million)

Figure 2. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Type: 2022 VS 2029

Figure 3. Inotersen Features

Figure 4. Tafamidis Features

Figure 5. Patisiran Features

Figure 6. Others Features

Figure 7. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Comparison by Application (2023-2029) & (US$ Million)

Figure 8. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Application: 2022 VS 2029

Figure 9. Hospital Pharmacies Case Studies

Figure 10. Retail Pharmacies Case Studies

Figure 11. Online Pharmacies Case Studies

Figure 12. Others Case Studies

Figure 13. Familial Amyloid Polyneuropathy Therapeutic Report Years Considered

Figure 14. Global Familial Amyloid Polyneuropathy Therapeutic Market Size (US$ Million), Year-over-Year: 2018-2029

Figure 15. Global Familial Amyloid Polyneuropathy Therapeutic Market Size, (US$ Million), 2018 VS 2022 VS 2029

Figure 16. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region: 2022 VS 2029

Figure 17. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Players in 2022

Figure 18. Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy Therapeutic as of 2022)

Figure 19. The Top 10 and 5 Players Market Share by Familial Amyloid Polyneuropathy Therapeutic Revenue in 2022

Figure 20. North America Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 21. North America Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2018-2029)

Figure 22. United States Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 23. Canada Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 24. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 25. Europe Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2018-2029)

Figure 26. Germany Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 27. France Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 28. U.K. Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 29. Italy Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 30. Russia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 31. Nordic Countries Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 32. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 33. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2018-2029)

Figure 34. China Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 35. Japan Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 36. South Korea Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 37. Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 38. India Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 39. Australia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 40. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 41. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2018-2029)

Figure 42. Mexico Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 43. Brazil Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 44. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 45. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2018-2029)

Figure 46. Turkey Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 47. Saudi Arabia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 48. Pfizer Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 49. Alnylam Pharmaceuticals Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 50. Ionis Pharmaceuticals Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 51. Corino Therapeutics Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 52. Proclara Biosciences Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 53. Arcturus Therapeutics Inc Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 54. Prothena Corporation Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 55. Eidos Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 56. FoldRx Pharmaceuticals Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 57. Akcea Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 58. GlaxoSmithKline (GSK) Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 59. Greenovation Biotech GmbH Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2023)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions